Clinical Trial Update: Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial is evaluating low-dose thalidomide as adjuvant therapy after radiofrequency ablation for hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Thalomid (thalidomide) (thalidomide)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Liver Cancer | Phase 2, Phase 3 | Status: UNKNOWN